 |
|
| Blog results | Results 1 - 10 of about 1,890 for bcr abl. (0.24 seconds) |
| Sorted by relevance Sort by date |
| Related Blogs: | Tipsukhon's Blog - http://tipsukhon.wordpress.com/ | |
| 11 Dec 2009 by Bioconjugate Chemistry Bioconjugate Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). MyJournals.org - RSS feed for news from... - http://www.myjournals.org/ |
| 23 Nov 2009 Clinical Proof-of-Concept Data to be Presented December 7, 2009 ARIAD to Hold Conference Call to Discuss Findings December 8, 2009 Nov 23, 2009 - ARIAD Pharmace. Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html [ More results from Drugs.com - Clinical Trials ] |
| 13 Oct 2009 by PLoS ONE These proteins in turn, link BCR-ABL to various signaling pathways indicated in cellular transformation. In this study we show that a triple mutant of BCR-ABL with mutations of the direct binding sites for GRB2, CBL, p62 DOK and CRKL, ... Elites TV - http://elitestv.com/ [ More results from Elites TV ] |
| 2 Nov 2009 The BCR-ABL inhibitor dasatinib achieves clinical remissions in chronic myeloid leukemia (CML) patients using a dosing schedule that achieves potent but transient BCR-ABL inhibition. In vitro, transient potent BCR-ABL inhibition with ... CANCER CELL - http://www.cell.com/cancer-cell/current [ More results from CANCER CELL ] |
| 28 Nov 2009 by rob Inhibition of Bcr-Abl by imatinib induced a hypersensitive phenotype both in Bcr-Abl(+) cell lines and in CD34(+) cells from CML patients. Importantly, cisplatin sensitivity of leukemic cells harboring an inactive Bcr-Abl greatly ... CMLHope.Com - http://cmlhope.com/ [ More results from CMLHope.Com ] |
| 8 Dec 2009 Tasigna is a potent and selective inhibitor of the Bcr-Abl protein that causes production of cancer cells in Ph+ CML[2],[3]. Upon initial reports of resistance in the Glivec registration trials, Novartis scientists created a new ... World Pharma News - http://www.worldpharmanews.com/ - References [ More results from World Pharma News ] |
| 7 Dec 2009 by Novartis Oncology Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) ... PR Hub - http://blog.taragana.com/pr/ |
| 23 Nov 2009 by DrugsNews ARIAD to Present Data on Pan-BCR-ABL Inhibitor AP24534 at 51st American Society of Hematology Meeting Clinical Proof-of-Concept Data to be Presented December 7, 2009 ARIAD to Hold Conference Call to Discuss Findings December ... Drugs Reviews | Dugs News - http://www.drugs-review.com/ |
| 5 Dec 2009 Over the past several years, tyrosine kinase inhibitors, which target BCR-ABL (an abnormal protein that drives the overproduction of white blood cells characteristic of leukemia), have become standard therapy for the treatment of CML. ... LifeSciencesWorld - http://www.lifesciencesworld.com/ |
| 6 Dec 2009 by Hochhaus A, Schenk T, Erben P, Ernst T,... The early detection of BCR-ABL mutants during therapy may aid in risk stratification as well as molecular-based treatment decisions. Therapeutic strategies of imatinib resistant disease include novel tyrosine kinase inhibitors with ... Research Papers, Journals, Pubmed - http://pubmeddy.com/ [ More results from Research Papers, Journals, Pubmed ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
